Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHEK1 | O14757 | 1/20 | 0.41 |
| ▸ | ACHE | P22303 | 1/20 | 0.41 |
| ▸ | PIM1 | P11309 | 8/20 | 0.38 |
| ▸ | MAPT | P10636 | 2/20 | 0.37 |
| ▸ | MAP4K1 | Q92918 | 7/20 | 0.36 |
| ▸ | NTRK1 | P04629 | 4/20 | 0.36 |
| ▸ | KIT | P10721 | 4/20 | 0.36 |
| ▸ | FLT3 | P36888 | 4/20 | 0.36 |
| ▸ | AURKA | O14965 | 2/20 | 0.34 |
| ▸ | AURKB | Q96GD4 | 2/20 | 0.34 |
| ▸ | INCENP | Q9NQS7 | 1/20 | 0.34 |
| ▸ | TPX2 | Q9ULW0 | 1/20 | 0.34 |
| ▸ | PIM3 | Q86V86 | 1/20 | 0.34 |
| ▸ | PIM2 | Q9P1W9 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1561170 | 0.87 | CHEK1 (0.38) | CHEK1ACHEPIM1MAPTAURKA | |
| SCHEMBL2215352 | 0.86 | CHEK1 (0.38) | CHEK1ACHEPIM1PIM3PIM2 | |
| SCHEMBL11934527 | 0.81 | FYN (0.43) | CHEK1ACHEPIM1 | |
| SCHEMBL1560881 | 0.80 | CHEK1 (0.44) | CHEK1ACHEPIM1MAPTMAP4K1 | |
| SCHEMBL11937135 | 0.80 | FYN (0.46) | CHEK1ACHEPIM1 | |
| SCHEMBL474985 | 0.77 | CHEK1 (0.46) | CHEK1ACHEPIM1MAPTMAP4K1 | |
| SCHEMBL11908677 | 0.77 | CHEK1 (0.47) | CHEK1ACHEPIM1MAPTMAP4K1 | |
| SCHEMBL473714 | 0.76 | MKNK1 (0.46) | CHEK1ACHEPIM1MAPTMAP4K1 | |
| SCHEMBL11907789 | 0.76 | CHEK1 (0.47) | CHEK1ACHEPIM1MAPTMAP4K1 | |
| SCHEMBL1560574 | 0.76 | CHEK1 (0.42) | CHEK1ACHEPIM1MAPTMAP4K1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110178053-A1 | AZACARBOLINE DERIVATIVES, PREPARATION METHOD THEREOF AND THERAPEUTIC USE OF SAME | SANOFI-AVENTIS (FR) | 2011-07-21 | — | — | US | claimed |
| US-20110178053-A1 | AZACARBOLINE DERIVATIVES, PREPARATION METHOD THEREOF AND THERAPEUTIC USE OF SAME | SANOFI-AVENTIS (FR) | 2011-07-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110178053-A1 | AZACARBOLINE DERIVATIVES, PREPARATION METHOD THEREOF AND THERAPEUTIC USE OF SAME | AOC3, CBR3, IDH3B | CHEK1 786/4885ACHE 4362/4885PIM1 2969/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.